Contact Dermatitis Treatment Guide

Contact dermatitis is one of the most common skin conditions I see in clinical practice — and also one of the most misunderstood. Patients often describe it as "just a rash," but behind that rash is either a chemical burning the skin's surface or an immune system mounting a full inflammatory response. Those are two completely different processes, and they require different approaches to diagnosis and treatment.

Contact dermatitis generates more than 8.4 million outpatient visits annually in the United States and accounts for roughly $1.5 billion in direct medical costs each year.^[2] It is the leading occupational skin disease, comprising 90–95% of all work-related skin conditions. Yet the path from "I touched something and my skin reacted" to an accurate diagnosis and sustained remission is surprisingly unstraightforward.

What I tell patients is this: the rash is just the signal. The real work is finding the source.

Irritant vs. Allergic Contact Dermatitis: Understanding the Difference

The distinction between irritant contact dermatitis (ICD) and allergic contact dermatitis (ACD) is not just academic — it determines whether a patient needs allergen avoidance alone, patch testing, or a different treatment strategy altogether.

Irritant Contact Dermatitis

ICD is a nonspecific skin response to direct chemical damage. No prior sensitization is required; nearly anyone exposed to a strong enough irritant for long enough will develop a reaction. The mechanism centers on keratinocyte disruption — the irritant breaches the skin barrier, triggering release of proinflammatory cytokines including IL-1α and TNF-α directly from epidermal cells.^[1]

Clinically, ICD burns and stings more than it itches. The acute form peaks quickly — within minutes to hours of exposure — then begins to resolve as long as the irritant is removed. Lesions stay sharply confined to the area of direct contact and do not spread. Chronic ICD from repeated low-grade exposure looks different: dry, fissured, thickened skin that resembles eczema and is common on the hands of healthcare workers, hairdressers, and cleaning staff.

Allergic Contact Dermatitis

ACD is a delayed-type (type IV) hypersensitivity reaction mediated by T cells. Two sequential phases drive the disease:

• Sensitization phase: On first exposure to an allergen (technically a "hapten" — a small molecule that binds skin proteins to become antigenic), Langerhans cells in the epidermis capture the hapten-protein complex, migrate to regional lymph nodes, and activate a clone of antigen-specific T cells. This takes 10–14 days and produces no visible skin reaction.
• Elicitation phase: On any subsequent exposure to the same allergen, the sensitized T cells recognize it within 24–72 hours. They migrate to the skin, release cytokines including IFN-γ and IL-17A, recruit additional immune cells, and generate the visible inflammatory response — erythema, vesicles, intense pruritus.^[3]

Unlike ICD, ACD spreads beyond the contact zone as the immune response amplifies. The itching is far more prominent. And crucially: once sensitized, a person remains sensitized for life. Trace exposures that previously caused no reaction can trigger significant flares.

In clinical practice, the two types often coexist. A patient who works with repeated wet exposure may have ICD that disrupts the skin barrier — which then makes it easier for allergens to penetrate and cause ACD on top of it. Sorting out which process is dominant matters enormously for treatment planning.

Common Contact Allergens: What Triggers Allergic Contact Dermatitis

More than 3,000 substances have been identified as contact allergens. In clinical practice, a smaller group accounts for the vast majority of reactions. Knowing these patterns helps narrow the differential before patch testing confirms the diagnosis.

Nickel

Nickel is the most common contact allergen worldwide — it causes more dermatitis than all other metals combined.^[4] Found in jewelry, belt buckles, watches, metal fasteners, and many everyday objects, nickel sensitization typically presents as a rash in areas of skin-metal contact: earlobes from earrings, the periumbilical area from belt buckles, and the wrists from watch clasps. A simple screening test — applying dimethylglyoxime solution to metal — turns pink in the presence of nickel. Once sensitized, a patient must coat nickel-containing objects, substitute with surgical steel or gold, or avoid them entirely.

Fragrances and Preservatives

Fragrance mix is the second most common allergen category in North America. Sensitization occurs through repeated exposure in personal care products — soaps, shampoos, lotions, perfumes, and cosmetics. Balsam of Peru (Myroxylon pereirae) is a related natural fragrance resin that cross-reacts with many synthetic fragrances. Preservatives such as formaldehyde releasers (quaternium-15, DMDM hydantoin) and methylchloroisothiazolinone/methylisothiazolinone (MCI/MI) found in many "rinse-off" and "leave-on" products are also frequent sensitizers, particularly for facial and eyelid dermatitis.

Rubber Accelerators

Rubber gloves are an occupational and personal care staple — and a significant source of contact sensitization. The culprits are chemical accelerators used in rubber manufacturing: thiurams, carbamates, and mercaptobenzothiazole. Healthcare workers, food service employees, and anyone who wears latex or synthetic gloves frequently are at elevated risk. Switching to accelerator-free nitrile gloves is the primary management strategy once sensitization is confirmed.^[5]

Topical Medications

Neomycin sulfate and bacitracin — widely used over-the-counter topical antibiotics — are among the most common sensitizers in North America. Patients applying these to chronic wounds or leg ulcers are particularly susceptible, because damaged skin is more permeable to allergens. In my experience, patients who report their wound "got worse" after applying a triple antibiotic ointment have allergic contact dermatitis to neomycin until proven otherwise.

Urushiol: Poison Ivy, Oak, and Sumac

Urushiol is the oily resin found in the leaves, stems, and roots of Toxicodendron plants — poison ivy, poison oak, and poison sumac. Sensitization affects an estimated 50–70% of adults in the United States.^[1] Urushiol binds to skin proteins within minutes of contact, forming the hapten-protein complex that drives sensitization. Once sensitized, even trace amounts — transferred from clothing, tools, or pet fur — trigger a reaction within 12–72 hours, often in the characteristic linear streaks where the plant brushed the skin.

One persistent misconception: the fluid inside poison ivy blisters does not spread the rash. The distribution of new lesions after the first day reflects differences in urushiol concentration and skin thickness at various contact points — thicker skin on the palms reacts later than thinner skin on the forearm.

Patch Testing: When to Refer and How It Works

Patch testing is the gold standard for identifying the specific allergen driving allergic contact dermatitis. It is not a blood test or a skin prick test — it deliberately replicates the delayed hypersensitivity reaction under controlled conditions on the back.

When Is Patch Testing Indicated?

Patch testing is appropriate when:

• Dermatitis is persistent, recurrent, or worsens despite treatment
• The rash involves the hands, face, or eyelids and the trigger is unclear
• Occupational exposure is suspected as a contributing cause
• A patient appears to react to topical medications, including corticosteroids themselves
• Standard eczema treatment produces incomplete results and allergen exposure cannot be excluded

Patch testing is not indicated for acute urticaria, immediate hypersensitivity reactions, or when the allergen is already clearly identified by history.

The T.R.U.E. Test Panel

The T.R.U.E. Test (Thin-layer Rapid Use Epicutaneous Test) is the only FDA-approved patch test system in the United States. It contains 35 preloaded allergens and allergen mixes — including nickel sulfate, fragrance mix, colophony, balsam of Peru, neomycin, potassium dichromate, thiuram mix, rubber mixes, and several preservatives — plus a negative control.^[4] The allergens are embedded in a hydrogel film on adhesive panels applied to the upper back.

The T.R.U.E. Test is convenient and standardized, but it has a key limitation: studies suggest it detects only about 66% of clinically relevant reactions compared to the broader North American Contact Dermatitis Group (NACDG) panel.^[2] For patients with occupational or complex presentations, a dermatologist may supplement with occupation-specific or custom allergen series.

How the Test Is Performed

Patch testing requires three office visits over approximately one week. Panels are applied to the upper back on day one, removed at 48 hours, and read at both 48 and 72–96 hours. Late readings matter because some allergens — particularly gold salts and corticosteroids — produce delayed reactions that only appear at the day-5 or day-7 reading.

Reactions are graded by the International Contact Dermatitis Research Group scale:

• (–): No reaction
• (IR): Irritant reaction — pustules, follicular pattern, or homogeneous erythema without infiltration
• (+/–): Equivocal — faint erythema only
• (+): Weak positive — erythema, infiltration, possibly papules
• (++): Strong positive — erythema, infiltration, papules, vesicles
• (+++): Extreme positive — bullous or ulcerative reaction

A positive result is only meaningful if it correlates with the patient's clinical history. The physician must determine relevance — is this allergen actually present in the patient's environment? This interpretation step is the most critical part of the process, and it directly drives the avoidance counseling that makes the difference between treatment success and failure.

Patients preparing for patch testing should stop oral and topical corticosteroids two to three weeks in advance, avoid sun exposure on the test area, and forgo vigorous exercise during the test period to prevent panel displacement or sweating.

Treatment: The Corticosteroid Potency Ladder, Calcineurin Inhibitors, and Wet Wraps

The treatment approach for contact dermatitis starts with one non-negotiable step: identify and remove the offending substance. Without allergen or irritant avoidance, no medication provides lasting benefit. That said, controlling the acute inflammation while avoidance takes effect is both necessary and achievable.

Topical Corticosteroids: Matching Potency to Location

Topical corticosteroids are the primary pharmacological treatment for contact dermatitis. Their anti-inflammatory mechanism involves suppression of phospholipase A2, reduction of prostaglandin and leukotriene synthesis, and inhibition of T-cell cytokine production. The challenge is selecting the right potency for the right body location.^[7]

The principle I follow: start at the potency the severity and location demand, achieve control quickly, then step down. Undertreating with a low-potency agent on a thick plaque on the hand achieves nothing but prolonged suffering. Overtreating the periorbital area with a high-potency agent causes cataracts and skin atrophy within weeks.

For poison ivy dermatitis specifically, topical corticosteroids applied within the first 12 hours — before significant vesiculation — can reduce severity. Once blistering is established, topical agents have limited penetration into the dermal reaction and oral prednisone is generally more effective for widespread disease.

Topical Calcineurin Inhibitors (TCIs)

Tacrolimus 0.1% ointment and pimecrolimus 1% cream are steroid-free anti-inflammatory agents that block calcineurin, a protein central to T-cell activation. Because they do not cause skin atrophy, they are the treatment of choice for facial, eyelid, neck, and intertriginous contact dermatitis where prolonged corticosteroid use is inappropriate.^[1]

Tacrolimus is the more potent of the two — equivalent in clinical trials to a mid-potency topical corticosteroid — and is appropriate for moderate-to-severe presentations on sensitive skin. Pimecrolimus is better suited to mild-to-moderate disease. Both are applied twice daily during active flares; frequency can be reduced for maintenance.

Patients often ask about the FDA black box warning on TCIs regarding a theoretical lymphoma risk from animal studies. The current clinical consensus, including the AAD position statement, is that the evidence does not support a causal link to malignancy in humans at approved doses, and these agents remain clinically useful and appropriate when indicated.^[7]

Wet Wrap Therapy

Wet wrap therapy is an adjunctive technique for severe acute contact dermatitis with significant skin barrier disruption. It works by enhancing absorption of topical corticosteroids, restoring skin hydration, and cooling the inflamed tissue. The technique involves applying a topical corticosteroid or emollient to the skin, covering with a damp inner layer of gauze or cotton clothing, then a dry outer layer. Wraps are worn for two to six hours or overnight and can be repeated daily for three to five days during acute flares.

Wet wrap therapy is particularly useful for hand and forearm dermatitis in occupational settings where the skin is repeatedly traumatized by wet work. It should be used under clinical supervision, as prolonged wet wraps over high-potency steroids increase systemic absorption.

Systemic Therapy

Systemic corticosteroids — typically oral prednisone — are indicated for severe, widespread, or rapidly progressing contact dermatitis. The standard dosing for significant poison ivy dermatitis is prednisone 0.5–1 mg/kg daily for five to seven days, followed by a gradual taper over another seven to ten days. Short dose packs (the standard six-day methylprednisolone pack) are often underdosed and too short for significant reactions, frequently resulting in rebound dermatitis once the taper ends.

Antihistamines — particularly sedating hydroxyzine or non-sedating cetirizine — help control pruritus as adjuncts but do not address the underlying inflammation. For severe, treatment-resistant ACD, dermatologists may consider dupilumab or other biologics, though evidence in pure contact dermatitis (as opposed to atopic dermatitis with superimposed ACD) remains limited.

Occupational Contact Dermatitis: Healthcare Workers, Hairdressers, and Construction

Occupational contact dermatitis (OCD) is the most common occupational skin disease, accounting for 90–95% of all work-related skin conditions.^[2] The prognosis is often poor without early intervention — one study found only 28% of healthcare workers with OCD recovered at six months after diagnosis. Prolonged disease reduces work productivity, impairs hand hygiene compliance, and in healthcare settings, can increase the risk of pathogen transmission from damaged skin.

Healthcare Workers

Hand dermatitis in healthcare workers is primarily ICD, driven by the frequency of hand hygiene: alcohol-based hand rubs, frequent handwashing with soap and water, prolonged glove use, and inadequate time for skin recovery between hygiene episodes. During the COVID-19 pandemic, incidence increased markedly as hand hygiene frequency surged across healthcare settings.^[5]

Practical workplace interventions with demonstrated benefit include switching to a gentler, lower-concentration alcohol hand rub, alternating hand rubs with mild wash formulations, replacing latex gloves with accelerator-free nitrile gloves, and temporary duty modification to reduce hand hygiene load during active dermatitis. Workers whose dermatitis does not improve with these measures — particularly those reacting to rubber accelerators or preservatives in glove materials — need patch testing and possible permanent glove substitution.

Hairdressers

Hairdressers face a dual hazard: ICD from repeated wet work and exposure to shampoos, conditioners, and bleaching agents; and ACD from sensitizing chemicals including para-phenylenediamine (PPD) in hair dyes, glyceryl thioglycolate in permanent wave solutions, and persulfates in bleaching powders. PPD is a particularly potent sensitizer — cross-reacting with azo dyes in clothing, local anesthetics in the caine group, and sulfonamide medications.

Sensitization to PPD effectively ends a hairdresser's career in hair coloring. Early identification through patch testing and allergen substitution (using PPD-free or low-sensitization dye systems) is critical to preventing career-ending sensitization.

Construction Workers

Construction workers encounter some of the most aggressive occupational allergens: wet cement (chromium sensitization from hexavalent chromium in Portland cement), epoxy resins and hardeners (diglycidyl ether of bisphenol A, aliphatic amines), and rubber in gloves and boots. Chromium allergy from cement exposure is one of the most persistent occupational ACD presentations — it is notoriously difficult to avoid completely, and many affected workers require job changes.

Ferrous sulfate added to cement reduces the hexavalent chromium content, and this intervention has been mandated in several European countries with measurable reductions in cement sensitization rates. In the United States, exposure control remains largely reliant on barrier protection and product substitution where feasible.

Prevention Strategies and Barrier Creams

For patients with confirmed contact allergens, the path to sustained remission runs through avoidance. That sounds straightforward, but nickel is present in hundreds of everyday objects, fragrances appear under dozens of ingredient names, and occupational allergens may be difficult to eliminate without significant workflow changes. Effective prevention requires knowing specifically what to avoid and where it hides.

Personalized Avoidance Counseling

Following a positive patch test, patients should receive a detailed avoidance plan that includes the specific allergen name, common sources in personal care and household products, likely cross-reactors, and safe alternatives. Resources like the American Contact Dermatitis Society's CAMP (Contact Allergen Management Program) and SkinSAFE provide ingredient-filtered product databases that take the guesswork out of shopping for personal care products.

Skin Barrier Protection at Work

Barrier creams — also called "pre-work" creams — form a film on the skin that reduces the penetration of irritants and some allergens. The evidence for their effectiveness in preventing ICD is moderate; they work better for repelling water-based irritants than oil-based ones, and their benefit is significantly reduced by inadequate application or incomplete coverage.

Gloves remain the most reliable physical barrier, but glove selection is itself a clinical decision. Latex gloves sensitize to rubber proteins; many synthetic alternatives use chemical accelerators that cause ACD. For patients who have reacted to rubber components, accelerator-free nitrile or polyvinyl chloride (PVC) gloves are the appropriate alternative.

Emollient Maintenance

Regular emollient use repairs and maintains the skin barrier, reducing both ICD from repeat low-level exposures and the skin's susceptibility to allergen penetration. Creams and ointments outperform lotions in barrier restoration; patients should apply them after each handwashing episode. In occupational settings, making emollients readily accessible — rather than requiring workers to seek them out — significantly improves compliance and outcomes.

The Role of Telehealth in Dermatology Assessment

Contact dermatitis is well suited to telehealth evaluation for many — though not all — presentations. The two pillars of clinical assessment are the morphology and distribution of the rash and a detailed exposure history. Both can be captured effectively through a structured virtual visit.

High-quality photographs of the affected skin, taken in natural light, allow a physician to assess distribution, morphology (erythema, vesicles, lichenification), and severity. A focused history covering symptom onset and timeline, potential exposures in the hours to days before onset, occupational environment, personal care products recently changed or added, and any prior similar reactions provides the clinical context needed to develop a differential diagnosis and initial treatment plan.

Telehealth is particularly effective for:

• Suspected poison ivy, oak, or sumac — the exposure history and linear blister pattern are often diagnostic
• Nickel allergy from new jewelry or accessories
• Irritant hand dermatitis in patients with known occupational wet work
• Facial or eyelid dermatitis from a recently changed personal care product
• Follow-up visits after initial in-person evaluation to assess treatment response

When telehealth reaches its limits — specifically, when the allergen cannot be identified, when the dermatitis does not respond to appropriate treatment, or when occupational disease requires formal patch testing — a referral to an in-person dermatologist or allergist is the right next step. Telehealth and in-person care are not competing approaches; they work best in sequence.

What I find in practice: patients who seek a telehealth evaluation early — before a manageable rash becomes a weeks-long ordeal — do significantly better. A prescription for an appropriate topical corticosteroid in the first 24 hours of a poison ivy reaction looks like a completely different clinical course compared to the same patient who waited a week and developed widespread blistering.

Frequently Asked Questions